AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28714534 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 50
Study 28714534 — intervention group
Group type: COMPARATOR
Intervention: AT-MAS
Number of subjects: 50
Study 25761833 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen replacement therapy (ART)
Number of subjects: 334
Study 25761833 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 334
Study 24486335 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ondansetron 4 mg + rHuPH20
Number of subjects: 12
Study 24486335 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ondansetron 4 mg
Number of subjects: 12
Study 24486335 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron 4 mg
Number of subjects: 12
Study 24486335 — intervention group
Group type: COMPARATOR
Intervention: Oral ondansetron 8 mg
Number of subjects: 12
Study 24570527 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic debridement
Number of subjects: 40
Study 24570527 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy and irrigation
Number of subjects: 40
Study 20527340 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of 0.25% bupivacaine with saline EVE (n=51)
Number of subjects: 157
Study 20527340 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of 0.25% bupivacaine without saline EVE (n=6)
Number of subjects: 157
Study 20527340 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of 0.25% L-bupivacaine (n=50)
Number of subjects: 157
Study 20527340 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of 0.3% L-bupivacaine (n=50)
Number of subjects: 157
Study 18785569 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 47
Study 18785569 — intervention group
Group type: COMPARATOR
Intervention: Mini-thoracotomy (MT)
Number of subjects: 47
Study 16134467 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment for high-risk prethreshold ROP
Number of subjects: 0
Study 16134467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12641681 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam/Syrpalta mixture
Number of subjects: 76
Study 12641681 — intervention group
Group type: COMPARATOR
Intervention: premixed midazolam solution
Number of subjects: 76
Study 10378492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimmersive VR exercise
Number of subjects: 13
Study 10378492 — intervention group
Group type: COMPARATOR
Intervention: Single bout of VR exercise
Number of subjects: 13
Study 9007599 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g intravenously every 8 h
Number of subjects: 61
Study 9007599 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 1 g intravenously every 8 h
Number of subjects: 61
Study 1501736 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced glutathione (1,200 mg)
Number of subjects: 20
Study 1501736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6663618 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual proportional feedback
Number of subjects: 20
Study 6663618 — intervention group
Group type: COMPARATOR
Intervention: Visual binary feedback
Number of subjects: 20
Study 6663618 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory proportional feedback
Number of subjects: 20
Study 6663618 — intervention group
Group type: COMPARATOR
Intervention: Auditory binary feedback
Number of subjects: 20
Study 31647007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimeticone-based test product (10 min application)
Number of subjects: 100
Study 31647007 — intervention group
Group type: COMPARATOR
Intervention: 0.5% permethrin-based reference product (45 min application)
Number of subjects: 100
Study 31647007 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Dimeticone and Permethrin)
Number of subjects: 100
Study 31647007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimeticone-based test product
Number of subjects: 100
Study 28019051 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 600
Study 28019051 — intervention group
Group type: COMPARATOR
Intervention: Traditional follow-up model
Number of subjects: 600
Study 25599428 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldenkrais method-based exercise (50 sessions, 2 times/week for 60 minutes)
Number of subjects: 30
Study 25599428 — intervention group
Group type: COMPARATOR
Intervention: Educational lectures (control group)
Number of subjects: 30
Study 23980044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression (IPC)
Number of subjects: 120
Study 23980044 — intervention group
Group type: COMPARATOR
Intervention: Control (non-IPC group)
Number of subjects: 120
Study 21422438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (defined as 25(OH)D lower than 20 ng/mL)
Number of subjects: 515
Study 21422438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (defined as 25(OH)D between 20 to 29 ng/mL)
Number of subjects: 515
Study 21422438 — intervention group
Group type: COMPARATOR
Intervention: Comparison of plasma 25(OH)D levels by race
Number of subjects: 515
Study 21422438 — intervention group
Group type: COMPARATOR
Intervention: Comparison of plasma 25(OH)D levels by gender
Number of subjects: 515
Study 21422438 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma 25(OH)D levels
Number of subjects: 515
Study 19661049 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 78
Study 19661049 — intervention group
Group type: COMPARATOR
Intervention: 90% oxygen
Number of subjects: 78
Study 16850022 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno‐venous hemodiafiltration (CVVHDF) (1‐2.5 l/h replacement fluid + 1‐1.5 l/h dialysate)
Number of subjects: 206
Study 16850022 — intervention group
Group type: COMPARATOR
Intervention: Continuous veno‐venous hemofiltration (CVVH) (1‐2.5 l/h replacement fluid)
Number of subjects: 206
Study 16850022 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno‐venous hemodiafiltration (CVVHDF)
Number of subjects: 206
Study 16850022 — intervention group
Group type: COMPARATOR
Intervention: Continuous veno‐venous hemofiltration (CVVH)
Number of subjects: 206
Study 16850022 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH and CVVHDF
Number of subjects: 206
Study 14764999 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory n-back task (assessing storage and rehearsal/maintenance)
Number of subjects: 0
Study 14764999 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Task (with significant central executive component)
Number of subjects: 0
Study 10340958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 40 mg anti-CD4
Number of subjects: 13
Study 10340958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 0.4 mg anti-CD4
Number of subjects: 13
Study 10340958 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of placebo
Number of subjects: 13
Study 8654059 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxified alcohol-dependent patients
Number of subjects: 521
Study 8654059 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of onset of alcoholism
Number of subjects: 521
Study 8654059 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety state, anxiety trait, and sex
Number of subjects: 521
Study 1497228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic children and adolescents with poor metabolic control
Number of subjects: 68
Study 1497228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic children and adolescents with prolonged evolution of diabetes
Number of subjects: 68
Study 1497228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubertal diabetic patients
Number of subjects: 68
Study 1497228 — intervention group
Group type: COMPARATOR
Intervention: Healthy children of the same ages
Number of subjects: 68
Study 6702616 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 30 mg/day
Number of subjects: 11
Study 6702616 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 120 mg/day
Number of subjects: 11
Study 6702616 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 240 mg/day
Number of subjects: 11
Study 6702616 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 480 mg/day
Number of subjects: 11
Study 6702616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31242943 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX)
Number of subjects: 294
Study 31242943 — intervention group
Group type: EXPERIMENTAL
Intervention: LINE-1 elements
Number of subjects: 294
Study 31242943 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in global DNA (hydroxy)methylation
Number of subjects: 294
Study 29794523 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous condition
Number of subjects: 87
Study 29794523 — intervention group
Group type: COMPARATOR
Intervention: Sequential condition
Number of subjects: 87
Study 26995378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice daily) + P2Y12 inhibitor
Number of subjects: 3000
Study 26995378 — intervention group
Group type: COMPARATOR
Intervention: DAPT (Aspirin 100 mg + P2Y12 inhibitor)
Number of subjects: 3000
Study 25174319 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified endoscopic operation
Number of subjects: 6
Study 25174319 — intervention group
Group type: COMPARATOR
Intervention: Control (osteotome operation)
Number of subjects: 6
Study 22009916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (10 mg), zeaxanthin (1 mg), astaxanthin (4 mg) and antioxidants/vitamins supplementation formula
Number of subjects: 145
Study 22009916 — intervention group
Group type: COMPARATOR
Intervention: No dietary supplementation
Number of subjects: 145
Study 19560695 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (0.05 mg/kg)
Number of subjects: 30
Study 19560695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (high dose: 0.43 mg/kg)
Number of subjects: 30
Study 19560695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (low dose: 0.05 mg/kg)
Number of subjects: 30
Study 16480759 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week calorie restricted diet
Number of subjects: 86
Study 16480759 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with aerobic exercise
Number of subjects: 86
Study 16480759 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-obese subjects)
Number of subjects: 86
Study 16271149 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 154
Study 16271149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (detuned short wave and detuned ultrasound)
Number of subjects: 154
Study 14562530 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 98
Study 14562530 — intervention group
Group type: COMPARATOR
Intervention: Three day cotrimoxazole
Number of subjects: 98
Study 14562530 — intervention group
Group type: COMPARATOR
Intervention: Five day cotrimoxazole
Number of subjects: 98
Study 10432067 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mefloquine-sulfadoxine-pyrimethamine (MSP)
Number of subjects: 1935
Study 10432067 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 1935
Study 7774210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 2182697 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol, 2.5 mg administered by nebulization
Number of subjects: 9
Study 217694 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyenyl phosphatidyl choline (PPC) plus clofibrate
Number of subjects: 67
Study 217694 — intervention group
Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 67
Study 31366325 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath® MAC videolaryngoscopic intubation with a stylet (group S, n=52)
Number of subjects: 104
Study 31366325 — intervention group
Group type: COMPARATOR
Intervention: McGrath® MAC videolaryngoscopic intubation without a stylet (group N, n=52)
Number of subjects: 104
Study 28064524 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaser Campaign (branded promotional postcards)
Number of subjects: 744
Study 28064524 — intervention group
Group type: COMPARATOR
Intervention: Standard Mail (no postcards)
Number of subjects: 744
Study 28064524 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaser Campaign
Number of subjects: 744
Study 28064524 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy clinics (Teaser Campaign)
Number of subjects: 744
Study 28064524 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice clinics (Teaser Campaign)
Number of subjects: 744
Study 25868409 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact low-frequency ultrasound (NLFU) + Standard Care (SC)
Number of subjects: 27
Study 25868409 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 27
Study 23792486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham injection + prompt laser with green laser treatment
Number of subjects: 0
Study 23792486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham injection + prompt laser with yellow laser treatment
Number of subjects: 0
Study 23792486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab + prompt laser
Number of subjects: 0
Study 23792486 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt laser only
Number of subjects: 0
Study 21719865 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable poly-L-lactic acid (PLLA)
Number of subjects: 233
Study 21719865 — intervention group
Group type: COMPARATOR
Intervention: Human collagen
Number of subjects: 233
Study 19542420 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic stent placement for gastric carcinoma
Number of subjects: 207
Study 19542420 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic stent placement for pancreatic carcinoma
Number of subjects: 207
Study 16409329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)(2)/CHX (gel)
Number of subjects: 64
Study 16409329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)(2)/CHX (solution)
Number of subjects: 64
Study 16409329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)(2)/saline paste
Number of subjects: 64
Study 16409329 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency file used
Number of subjects: 64
Study 16409329 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency file not used
Number of subjects: 64
Study 12115589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary consultation aimed at reducing salt and increasing vitamin C and carotenes over 1 year
Number of subjects: 59
Study 12115589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 59
Study 9932568 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline infusion
Number of subjects: 52
Study 9932568 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone gel
Number of subjects: 52
Study 7479199 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, oral, 20‐mg dose of glipizide
Number of subjects: 6
Study 7479199 — intervention group
Group type: COMPARATOR
Intervention: Divided-dose regimens totaling 20 mg each (simulating delayed absorption over 2, 4, and 8 hours)
Number of subjects: 6
Study 2215093 — intervention group
Group type: EXPERIMENTAL
Intervention: Surecut 0.6 mm liver biopsy
Number of subjects: 77
Study 2215093 — intervention group
Group type: COMPARATOR
Intervention: Menghini biopsy
Number of subjects: 77
Study 378734 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine (25 mg) and acetaminophen (325 mg) combination
Number of subjects: 200
Study 378734 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine (25 mg) alone
Number of subjects: 200
Study 378734 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (325 mg) alone
Number of subjects: 200
Study 378734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 31923642 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score (0-15) derived from factors including age, smoking habits, family history of colorectal cancer, and presence of neoplasia in the distal colorectum.
Number of subjects: 7954
Study 31923642 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score of 4 points or higher indicating high risk for APN.
Number of subjects: 7954
Study 31923642 — intervention group
Group type: EXPERIMENTAL
Intervention: C-statistic of the scoring system.
Number of subjects: 7954
Study 31923642 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to refer based on scoring system.
Number of subjects: 7954
Study 31923642 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to screen based on scoring system.
Number of subjects: 7954
Study 30134294 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined HIV care delivery model
Number of subjects: 0
Study 30134294 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (TDF/3TC/EFV)
Number of subjects: 0
Study 30134294 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load testing (2 tests/year)
Number of subjects: 0
Study 30134294 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized ART scale-up with lowest-cost ART
Number of subjects: 0
Study 30134294 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual viral load testing
Number of subjects: 0
Study 30134294 — intervention group
Group type: EXPERIMENTAL
Intervention: Governmental healthcare worker salaries
Number of subjects: 0
Study 30134294 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined care delivery costs
Number of subjects: 0
Study 30134294 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention in care and viral suppression levels
Number of subjects: 0
Study 27780932 — intervention group
Group type: EXPERIMENTAL
Intervention: High sPDL1 (≥0.94 ng/mL)
Number of subjects: 158
Study 27780932 — intervention group
Group type: COMPARATOR
Intervention: Low sPDL1 (<0.94 ng/mL)
Number of subjects: 158
Study 26419096 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS group (1,500 ml ORS 6 to 2 hours before anesthesia)
Number of subjects: 40
Study 26419096 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing by mouth from 6 hours before anesthesia)
Number of subjects: 40
Study 23916551 — intervention group
Group type: EXPERIMENTAL
Intervention: 320‐section volume imaging using AIDR (group A)
Number of subjects: 150
Study 23916551 — intervention group
Group type: COMPARATOR
Intervention: 320‐slice volume scan without AIDR (group B)
Number of subjects: 150
Study 23916551 — intervention group
Group type: COMPARATOR
Intervention: 64‐section helical imaging without AIDR (group C)
Number of subjects: 150
Study 20152024 — intervention group
Group type: EXPERIMENTAL
Intervention: IP6 + Inositol
Number of subjects: 14
Study 20152024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19017850 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 40
Study 19017850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated shoe inserts
Number of subjects: 40
Study 19017850 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated shoe inserts after custom-made orthoses
Number of subjects: 40
Study 17079221 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with SLI
Number of subjects: 0
Study 17079221 — intervention group
Group type: COMPARATOR
Intervention: Syntactic complexity
Number of subjects: 0
Study 17079221 — intervention group
Group type: COMPARATOR
Intervention: Morphological complexity
Number of subjects: 0
Study 17079221 — intervention group
Group type: COMPARATOR
Intervention: Complexity of stimuli
Number of subjects: 0
Study 12841541 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + GH-releasing peptide-6 (GHRP-6)
Number of subjects: 21
Study 12841541 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 21
Study 10225245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 72
Study 10225245 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study 8665876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive ketorolac 30 mg administered 30 min before surgical incision
Number of subjects: 77
Study 8665876 — intervention group
Group type: COMPARATOR
Intervention: Post‐surgical ketorolac 30 mg administered at the end of the surgical procedure
Number of subjects: 77
Study 2194133 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg subcutaneously twice per week for 3 weeks, followed by 1 intramuscular injection of 40 micrograms HB-Vax and 3 subsequent injections of thymopentin)
Number of subjects: 20
Study 2194133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 346252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus timolol
Number of subjects: 38
Study 346252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus timolol plus hydralazine
Number of subjects: 38
Study 346252 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide plus placebo plus hydralazine
Number of subjects: 38
Study 31319174 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise during HPV vaccination
Number of subjects: 0
Study 31319174 — intervention group
Group type: COMPARATOR
Intervention: No exercise during HPV vaccination
Number of subjects: 0
Study 27997472 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated mobilization (staff dedicated to assist transfers and walking from postoperative days 0-3)
Number of subjects: 99
Study 27997472 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated mobilization
Number of subjects: 99
Study 27997472 — intervention group
Group type: COMPARATOR
Intervention: Usual care (including preoperative education about early mobilization with postoperative daily targets)
Number of subjects: 99
Study 26718606 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin (2.5 mg/d, increased to 5 mg/d)
Number of subjects: 1030
Study 26718606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study 26718606 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin
Number of subjects: 1030